MaldivesTuberculosis profile
Population  2016 <1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.017 (0.013–0.021) 3.9 (3.1–4.9)
Mortality (HIV+TB only) 0 (0–0) 0 (0–0)
Incidence  (includes HIV+TB) 0.21 (0.16–0.27) 49 (38–62)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.23 (0.15–0.33)
Incidence (MDR/RR-TB)** <0.01 (0–0.011) 0.95 (0–2.6)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.011 (<0.01–0.013) 0.05 (0.037–0.062) 0.06 (0.045–0.076)
Males 0.011 (<0.01–0.014) 0.14 (0.1–0.17) 0.15 (0.11–0.19)
Total 0.022 (0.017–0.028) 0.19 (0.14–0.24) 0.21 (0.16–0.27)
TB case notifications, 2016  
Total cases notified 169
Total new and relapse 169
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status <1%
          - % pulmonary 46%
          - % bacteriologically confirmed among pulmonary 100%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.08 (0.06–0.11)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 1 100%
          - on antiretroviral therapy 1 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1
(0–4)
Estimated % of TB cases with MDR/RR-TB 1.7% (0.04–9.1) 0% (0–0)  
% notified tested for rifampicin resistance 36% 0% 59
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 1, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 2, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 83% 153
Previously treated cases, excluding relapse, registered in 2015   0
HIV-positive TB cases registered in 2015   0
MDR/RR-TB cases started on second-line treatment in 2014   0
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (93–100)
TB financing, 2017  
National TB budget (US$ millions) <1
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-05-24 Data: www.who.int/tb/data